A new study conducted by the World Health Organization (WHO) suggests that in addition to providing significant improvements in public health, investment in the diagnosis and prevention of ...
Produced by the National Institute of Allergy and Infectious Diseases (NIAID), this digitally colorized scanning electron microscopic (SEM) image, depicts a grouping of red-colored, rod shaped, ...
Bacille Calmette-Guérin (BCG) revaccination didn't help prevent sustained Mycobacterium tuberculosis infection in initially uninfected adolescents without HIV in a randomized trial from South Africa.
Dolutegravir-based ART with isoniazid was safe and effective for tuberculosis prevention in ART-naïve HIV patients, leading to rapid viral suppression. The study reported minimal adverse events, with ...
Global progress to reduce the number of people who fall ill with tuberculosis (TB) has stalled. More than 10 million people are still getting sick every year, and the COVID-19 pandemic overwhelmed ...
Despite efforts to eliminate the disease, 13 million Americans are living with latent tuberculosis infection, according to the most recent statistics from the National Health and Nutrition Examination ...
Cite this: Risk and Prevention of Tuberculosis and Other Serious Opportunistic Infections Associated with the Inhibition of Tumor Necrosis Factor - Medscape - Nov 01, 2006. KL Winthrop is an Assistant ...
New guidelines update ART choices, endorse long-acting injectables, refine infant feeding advice, and prioritise shorter TB ...
Tuberculosis (TB) is mostly forgotten, but certainly not gone. We often associate TB with bygone times. In 1882, the consumption, as it was often called then, killed one in seven people in Europe and ...
Tuberculosis is once again the world’s deadliest infectious disease, and the number of people newly diagnosed with TB reached a new high in 2023, according to new global estimates. Last year, 10.8 ...
TB remains the leading cause of death among people living with HIV. Uganda is a high TB-burden country, and HIV accelerates ...